Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: An estimate of the treatment cost, $13/month was obtained from the Cystic Fibrosis Foundation The absolute benefit, 41% of those using the treatment avoided complications, is compared with the 16% of those not using the salt water treatment. The treatment was noted as having potentially limited benefit because the prospect of adding an additional 30 minutes of treatment to an already extensive treatment regimen could be a burden. No mention was made of the small (5%) number of patients using the treatment that experienced adverse events. The article describing the two studies failed to detail the nature of the studies. They were two randomized clinical trials. The article explains that cystic fibrosis is a genetic disease and a rare disorder. The reporter contacted a clinician from a cystic fibrosis center that did not appear to have ties to either study. She also included commentsfrom an editorial on the two studies. The advantage of this treatment is that it may reduce the incidence of some serious complications of the disease. The article is clear that this treatment does not cure cystic fibrosis and is used in addition to other therapies, not instead of them. The treatment is available at the centers actually involved in the studies; comments from a third clinician directing treatment of individuals with cystic fibrosis but not involved in the studies indicates that use of this treatment has already been picked up by other groups specializing in cystic fibrosis care. While this could suggest that other groups specializing in cystic fibrosis care might also be offering this treatment, the actual availability is not clear. This article reports on the use of a novel adjunct treatment in the management of cystic fibrosis

A: Saltwater therapy helps ease cystic fibrosis
****
Q: Seasoned explorer Robert Swan and his 23-year-old son Barney will begin their eight week, 600-mile expedition on Wednesday, hoping to show renewable energy can work in extreme conditions and prove a viable alternative to fossil fuels. "For the first time in history we will be surviving only on renewable energy. It's never been done," 61-year-old polar veteran Swan, the first person to walk to both the North and South poles, told Reuters. The Swans' 5,000 daily calorie intake will come from sustainable and energy-giving foods, such as grains and almond bars, to help them overcome temperatures of -40 degrees Celsius and the obvious risks of frostbite, altitude sickness and snow blindness. Perpetual sunlight will charge the solar panels, which will power a NASA-designed ice melter to provide them with enough water for drinking and cooking. "Water is gold down in Antarctica, without it you're going to be dying pretty quickly, as dad always reminds me," said Barney Swan. While their aim is to complete the trek using just solar energy, under extreme weather conditions they'll turn to an advanced biofuel made out of wood chip waste. "The fuels have been tested to minus 60 degrees Celsius...it won't get as cold as minus 60. We may get minus 40 which is, trust me, cold enough," the elder Swan said.

A: Father-son team plans Antarctic trek powered by renewable energy.
****
Q: "The article is sufficiently clear that the drug is generic and inexpensive. Because this use would be novel, and not used as an alternative to existing treatments, more information about its cost is not required. While the report uses study data to describe the findings, it does not clarify what those findings mean to people who have had strokes. The findings indicate the drug group (NIHSS scale rating 1.6) had ""little nor no disability,"" and the placebo group (rating 6.5) ""the high end of mild disability."" Translating these into specific symptoms (slurred speech, difficulty walking, cognitive impairment, etc.) would be useful. It's also not clear how high the stroke scale goesto 10? 15? 20? Knowing that would help readers understand the magnitude of the difference. Finally, the study found that there was no difference in heart attacks, additional strokes or deaths between the two groups. Data on these critical outcomes should have been reported. One credible source states that the antibiotic has a well established safety record. Other sources confirm this indirectly. Because the potential benefit is so largepreventing permanent brain damage resulting from a strokeminor side effects are not essential to mention. It would have been useful to know, however, whether this drug could interact with clot-busting medications if they are given within the three-hour window. The article indicates that the study is small and the first to produce these findings. It also explains that it was an ""open label"" study, meaning the patients knew whether they were getting the antibiotic or a placebo. Several sources reiterate that the findings are preliminary and require replication. The reporter also mentions that a similar study of a neuroprotective agent had promising results but was later shown ineffective in a larger study. This context is very useful; it discourages readers from jumping to conclusions about this study's value. The article does nothing to exaggerate the effects of stroke or the drug's capacity to minimize them. The writer interviews four independent sources in addition to the study author, an unusual amount of reporting on a single study that adds to the story's value. The article makes clear that thestudywas not funded by an interested party, which also adds credibility to the findings. The article makes clear that there are no treatment options outside the 3-hour treatment window when administration of the IV clot-buster tPA is effective at protecting against brain damage. The article makes clear that the drug is cheap and widely available, but properly adds that any use as a treatment for stroke would be off-label at a doctor's discretion. The report makes clear that the use of the antibiotic as a neuroprotective agent is novel, though the product is widely used for other purposes. There is no evidence the article was based on the press release."

A:
Antibiotic might help after stroke, study says
****